Allogeneic CD19 chimeric antigen receptor-natural killer (CAR-NK) cell therapy showed promise in patients with relapsed or refractory systemic lupus erythematosus (SLE), with sustained efficacy. The ...

Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing ...

Researchers at the VIB-KU Leuven Center for Cancer Biology have uncovered that "natural killer" cells (NK), a type of immune cell, may actually be hindering the immune system's ability to attack ...

Vycellix to attend key upcoming investor & partnering events to share progress reports for its allogeneic cancer cell therapy ...

Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with the potential to overcome key limitations of current chimeric antigen ...

The partnership with Vinmec Healthcare System demonstrates the confidence in our technology and supports our long-term ...

Scientists at McGill University have found a way to supercharge the immune system’s natural killer (NK) cells, helping them break through the defenses tumors use to stay alive. By temporarily blocking ...

Cell therapy, often referred to as a form of regenerative medicine, uses living cells or cell-derived products to support the ...

SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma manufacturing and enhance cell and gene therapy development, today announced ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...